An observational study in Non Metastatic HER2 Positive Breast Cancer, sponsored by Blida 1 University. Recruiting at 1 site in Algeria. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Blida 1 University · Observational
This study aims to find out how effective and well-tolerated the subcutaneous form of trastuzumab-pertuzumab (known as Phesgo) is when given before surgery (neoadjuvant treatment) to Algerian women with early stage, HER2-positive breast cancer.
The study will take place in three oncology centers in Algeria (Blida, Aïn Defla, Médéa) and include around 70 adult women diagnosed with non-metastatic HER2-positive breast cancer. Participants will receive Phesgo along with standard chemotherapy over about 18 weeks, followed by surgery.
The main goal is to measure how many women achieve complete destruction of invasive cancer in the breast and nearby lymph nodes (pathological complete response, pCR). We will also look at other outcomes such as how many women can keep their breast, any side effects, quality of life, satisfaction with treatment, and factors that might predict response.
Results from this real-world study will help assess whether Phesgo can simplify treatment delivery, reduce hospital burden, and improve care access in Algeria where healthcare resources are often stretched.
Adult female patients diagnosed with HER2-positive, non-metastatic breast cancer and eligible for neoadjuvant therapy according to local clinical practice in Algeria. Participants will be recruited from three oncology centers: Anti Cancer Center of Blida, public hospital of Aïn Defla, and public hospital of Médéa.
Exclusion Criteria:
Pathological Complete Response (pCR) Rate
The proportion of participants with no residual invasive cancer in the breast and axillary lymph nodes after completion of neoadjuvant therapy, defined as ypT0/Tis ypN0 according to standard pathological assessment. Pathological evaluation will be performed on surgical specimens by certified pathologists following local and international guidelines.
Time frame: At the time of surgery, approximately 18-24 weeks after the start of neoadjuvant treatment.
Breast-Conserving Surgery Rate
Proportion of participants undergoing breast-conserving surgery after completion of neoadjuvant therapy. Determined from surgical records.
Time frame: At the time of surgery, approximately 18-24 weeks after the start of neoadjuvant treatment.
Incidence of Adverse Events
Frequency and severity of treatment-related adverse events, graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version in use at study initiation.
Time frame: From first dose of study treatment until 30 days after last dose (approximately 20-22 weeks).
Patient Satisfaction With Treatment
Proportion of participants reporting satisfaction with subcutaneous administration of trastuzumab-pertuzumab (Phesgo), as assessed by a study-specific satisfaction questionnaire.
Time frame: Post-surgery (approximately 24-28 weeks after treatment initiation).
Predictive Factors of Response
Association between clinical, pathological, and biological characteristics (including biomarkers) and pathological complete response.
Time frame: From baseline to surgery (approximately 18-24 weeks after treatment initiation).
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.